What is 1P-LSD?
1-propionyl-d-lysergic acid diethylamide (1P-LSD) is a novel semi-synthetic psychedelic substance that belongs to a chemical class of lysergamide and produces LSD-like psychedelic effects on administration. It is structurally analogous to psychedelic lysergamides like LSD and ALD-52.
This was first introduced in grey market in January 2015 as a research chemical. The discoverer is unknown, but it is most likely been synthesized in an academic setting. This substance can potentially be used as a prodrug for LSD. It is non-habit forming but tolerance to effects of 1P-LSD develops quickly after ingestion. Though 1P-LSD is not considered as addictive or toxic, in contrast to LSD, it is, however a very potent and long-lasting hallucinogenic substance so it is strongly suggested to prepare proper amount cautiously and utilize all other harm reduction practices while using it. As adverse effects were previously reported which includes anxiety, paranoia, delusions and psychosis, most commonly in patients with mental disorders.
Structurally, it resembles to LSD, and the name 1P-LSD is due to the propionyl group which is attached to the nitrogen of the polycyclic indole group of LSD. The propionyl consists of the carbonyl chain CH3CH2CO- attached to an amino group. 1P-LSD chemical structure consists of a polycyclic group that bears the bicyclic hexahydro indole bound to a bicyclic quinoline group. Moreover, an N,N-diethyl carboxamide is attached at a location of carbon 8 of quinoline.
Bioactivity of 1P LSD
Pharmacologically, 1P-LSD most likely acts as a 5HT2A partial agonist. And for its prominent psychedelic effects, that is linked with the efficacy of substance at the 5HT2A receptors, which is distributed throughout the brain. As it has structural similarity with LSD, it also shows binding activity at monoamine receptors, such as dopamine and norepinephrine. But right now the exact role of these interactions and the psychedelic experience is under investigation stage.
In humans, the scientific literature has very little data on the pharmacological properties, metabolism and toxicity of 1P-LSD. The reason for non-existence of human consumption was that it was not available until 2015, after that, online vendors started selling it as a gray area research chemical. It was first marketed as a legal alternative to LSD and other lysergamides like ALD-52, ETH-LAD, AL-LAD.
Expected Physical effects of N,N-Diethyl-7-methyl-4-propanoyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
The drug substance is expected to cause stimulation, spontaneous physical sensations, physical euphoria, tactile enhancement, stamina enhancement, appetite suppression, bodily control enhancement, difficulty in urination, excessive yawning, nausea, increase in blood pressure, heart rate and perspiration, muscle spasms and contractions, pupil dilation, increase in salivation, vasoconstriction, seizure among some physical effects.
The cognitive effects the person likely to experience includes anxiety, paranoia, analysis enhancement, conceptual thinking, creativity enhancement, emotion and novelty enhancement, suppression of personal bias, increase in focus and immersion, enhancement of suggestibility and personal meaning, memory suppression, personality regression, cognitive euphoria, delusions, Deja Vu, ego replacement, increase in music appreciation, libido and sense of humour (laughter fits), thought loops, disorganization and acceleration, time distortion and wakefulness.
It also exerts visual effects such as enhancement of colour, pattern recognition and visual acuity. Also it imparts distortions like colour shifting, drifting, tinting, tracers, after images, scenery slicing, symmetrical texture repetition, perception distortions etc. It causes a visual geometry of level 8A dominant or 8B, under right circumstances.
It induces strong hallucinations that might include internal and external hallucination, transformations and machinescapes etc. It also causes auditory, multi-sensory (synaesthesia) and transpersonal effects (spirituality and existential self-realization).
Dosage information for 1-propionyl-d-lysergic acid diethylamide
The minimal amount (threshold) of 1P-LSD required for producing action starts from a dose of 25 µg and mild effects are reported when taken in dosage of around 25 – 75 µg (light). The common dose varies from 75 – 150 µg, while a dose of 150 – 300 µg has been administered when a stronger effect is desirable. The dosages above 300 µg are considered heavy and caution must be taken. It is advisable not to mix drug with other substances.
The duration of action of drug lasts from 8 – 12 hours. The onset of action is from 20 – 60 minutes and one can experience come up within 45 – 120 minutes. The peak affects are observed at 3 – 5 hours, while it begins to offset after 3 – 5 hours.
The after effects can be experienced for about 6 – 24 hours after the last dose taken.
1-propionyl-d-lysergic acid diethylamide,
Street name: are same used for LSD, such as acid, blotter, stars, cheer, dose, blaze etc.